# OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug Development

## TL;DR

This paper explores OPA1's role in cancer, focusing on its molecular mechanisms and potential as a drug target.

## Contribution

The paper highlights OPA1's GTPase domain and Interface 7 as novel therapeutic targets in cancer.

## Key findings

- OPA1 dysregulation contributes to cancer initiation and progression.
- OPA1's GTPase domain and Interface 7 are promising therapeutic targets.
- Computational approaches could identify new OPA1 modulators for cancer treatment.

## Abstract

Mitochondria are highly dynamic organelles that integrate metabolic regulation, signal transduction, and programmed cell death with their canonical role in adenosine triphosphate (ATP) production. Their ability to undergo continuous remodeling through the opposing processes of fusion and fission is essential for maintaining cellular homeostasis, preserving organelle quality control, and enabling adaptive responses to metabolic and oxidative stress. Among the core regulators of mitochondrial dynamics, the dynamin-related guanosine triphosphatase (GTPase) OPA1 plays a central role in inner membrane fusion, cristae architecture maintenance, bioenergetic efficiency, and the modulation of redox balance and apoptotic signaling. Accumulating evidence indicates that dysregulation of OPA1 expression or activity contributes to the initiation and progression of multiple malignancies, underscoring its importance in tumor cell survival, proliferation, metabolic adaptation, and resistance to stress. Here, we summarize current knowledge on OPA1 dysregulation in cancer and, based on preliminary, unpublished in silico analyses, we highlight the growing relevance of OPA1 as a therapeutic target, particularly through its GTPase domain and the still understudied Interface 7. Overall, these findings outline how integrated computational approaches could potentially guide the identification of novel OPA1 modulators, offering a conceptual framework that highlights OPA1 as a promising, yet still largely underexplored, target in oncology.